Zentek (TSE:ZEN)
:ZEN
Top Page
Zentek
(ZEN)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.73
▼(-28.92% Downside)
Action:ReiteratedDate:03/03/26
The score is primarily held back by weak financial performance—limited revenue scale, negative margins, and continued cash burn—only partially offset by a low-leverage balance sheet. Technicals add pressure as the stock trades below key moving averages with a negative MACD, while valuation signals are inconclusive due to negative earnings and no dividend data.
Positive Factors
Balance sheet strength
Low leverage and modest debt provide durable financial flexibility. With debt-to-equity well below 0.2, Zentek can fund near-term R&D, pursue partnerships or licensing, and withstand operating losses longer without immediate solvency pressure, reducing short-term refinancing risk.
Negative Factors
Tiny revenue scale
Sub-$1M TTM revenue means the business is far from commercial scale; fixed costs dominate and losses are large relative to sales. Without meaningful revenue expansion, the company cannot absorb overhead or demonstrate sustainable margins, raising execution and viability risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Low leverage and modest debt provide durable financial flexibility. With debt-to-equity well below 0.2, Zentek can fund near-term R&D, pursue partnerships or licensing, and withstand operating losses longer without immediate solvency pressure, reducing short-term refinancing risk.
Read all positive factors
Zentek (ZEN) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$81.73M
Dividend YieldN/A
Average Volume (3M)66.24K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth2225.73%
EPS Growth25.94%
CountryCA
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.02
Shares Outstanding107,543,560
10 Day Avg. Volume86,681
30 Day Avg. Volume66,239
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)11.24
Price to Sales (P/S)190.02
P/FCF Ratio-26.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zentek Business Overview & Revenue Model
Company Description
Zentek Ltd. (ZEN) is a Canadian technology company specializing in advanced materials and innovative solutions for various industries, including healthcare, energy, and environmental sectors. The company is focused on developing and commercializin...
How the Company Makes Money
null...
Zentek Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 942.88K | 872.50K | 29.82K | 72.86K | 339.67K | 2.35K |
| Gross Profit | -705.11K | 192.49K | -385.06K | -780.48K | -275.04K | -124.44K |
| EBITDA | -7.86M | -9.35M | -11.08M | -13.75M | -11.27M | -3.73M |
| Net Income | -8.08M | -10.04M | -11.70M | -14.41M | -38.69M | -3.87M |
Balance Sheet | ||||||
| Total Assets | 17.38M | 18.40M | 22.59M | 33.29M | 37.98M | 30.25M |
| Cash, Cash Equivalents and Short-Term Investments | 1.80M | 121.48K | 3.52M | 10.36M | 26.68M | 3.09M |
| Total Debt | 1.90M | 680.47K | 1.24M | 1.61M | 2.23M | 404.32K |
| Total Liabilities | 5.04M | 3.65M | 2.41M | 2.90M | 3.44M | 2.79M |
| Stockholders Equity | 12.34M | 14.75M | 20.17M | 30.38M | 34.55M | 27.46M |
Cash Flow | ||||||
| Free Cash Flow | -6.00M | -6.28M | -8.37M | -15.23M | -11.97M | -2.05M |
| Operating Cash Flow | -5.62M | -6.28M | -8.05M | -12.96M | -7.99M | -1.79M |
| Investing Cash Flow | 1.75M | 358.65K | 1.88M | -2.31M | -7.25M | -1.23M |
| Financing Cash Flow | 4.18M | 2.52M | -665.47K | -1.05M | 38.82M | 5.31M |
Zentek Technical Analysis
Negative
1.02
Price Trends
0.86
Negative
0.96
Negative
1.10
Negative
Market Momentum
-0.04
Positive
41.74
Neutral
28.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZEN, the sentiment is Negative. The current price of 1.02 is above the 20-day moving average (MA) of 0.80, above the 50-day MA of 0.86, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 41.74 is Neutral, neither overbought nor oversold. The STOCH value of 28.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZEN.
Zentek Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$113.05M | 211.50 | 0.87% | ― | 2.14% | -83.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$63.05M | -32.47 | ― | ― | -21.89% | 26.36% | |
46 Neutral | C$81.73M | -9.55 | -61.26% | ― | 2225.73% | 25.94% | |
41 Neutral | C$33.74M | -21.43 | -434.25% | ― | ― | 10.97% | |
39 Underperform | C$40.16M | -12.93 | 72.34% | ― | ― | 10.49% |
* Healthcare Sector Average
TSE:ZEN
Zentek
0.76
-0.78
-50.65%
TSE:ARCH
Arch Biopartners
0.60
-1.18
-66.29%
TSE:BUX
BioMark Diagnostics
0.60
0.34
130.77%
TSE:MDP
Medexus Pharmaceuticals Inc
3.50
1.20
52.17%
TSE:SONA
Sona Nanotech Inc
0.30
0.02
9.26%
Zentek Corporate Events
Business Operations and Strategy
Zentek Taps ICP Securities for Algorithmic Market-Making to Boost Liquidity
Positive
Apr 1, 2026
Zentek Ltd., a Canadian IP development company specializing in graphene-enabled and advanced material technologies for clean air, next-generation materials and critical minerals, operates key platforms including Albany Graphite, ZenGUARD™ an...
Business Operations and StrategyProduct-Related Announcements
Zentek’s Triera Unit Launches Aptamer-Focused CRO to Target High-Growth Diagnostic Markets
Positive
Mar 25, 2026
Triera Biosciences, a Zentek subsidiary, is launching contract research organization services that combine custom aptamer discovery, biosensor engineering, and optional machine-learning classification for pharmaceutical, biotechnology, and diagnos...
Business Operations and StrategyLegal Proceedings
Zentek Wins Favorable Court Ruling, Clearing $6 Million in Claims
Positive
Mar 13, 2026
Zentek Ltd. has secured a favorable ruling from the Ontario Superior Court of Justice, which dismissed substantially all claims brought by company founder and former CEO Aubrey Eveleigh and his consulting firm, originally valued at more than $6 mi...
Business Operations and Strategy
Zentek Deepens Government and First Nations Ties Around Albany Graphite at PDAC 2026
Positive
Mar 9, 2026
Zentek used the PDAC 2026 convention to deepen government and Indigenous relationships around its Albany Graphite Project in Northern Ontario, emphasizing the deposit’s nuclear-grade purity and its strategic role in Canada’s critical m...
Business Operations and StrategyProduct-Related Announcements
Zentek Launches U.S. Pilot with Quality Filters to Advance Air Filtration Push
Positive
Mar 4, 2026
Zentek has launched an 8- to 12-week pilot evaluation program with U.S.-based Quality Filters Inc. to test the integration of its proprietary air filtration media into Quality’s commercial HVAC and industrial filtration product lines. The pr...
Business Operations and StrategyPrivate Placements and Financing
Zentek Taps Government Programs to Fast-Track Albany Graphite Development
Positive
Feb 26, 2026
Zentek has outlined a comprehensive government engagement strategy to accelerate development of its Albany Graphite Project toward a new Preliminary Economic Assessment and ultimately a Pre-Feasibility Study. Positioned as a potential domestic sou...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Zentek Wins Nasdaq Extension to Meet Minimum Bid Price Rule
Negative
Feb 26, 2026
Zentek Ltd. has secured a 180-day extension from Nasdaq to regain compliance with the exchange’s minimum bid price requirement, giving the company until August 24, 2026, to lift its share price back above US$1.00 for at least ten consecutive...
Business Operations and Strategy
Zentek Sharpens Strategy Around High‑Purity Albany Graphite and Core Platforms
Positive
Feb 17, 2026
Zentek outlined a strategic reset centered on strict capital discipline, execution against clearly defined milestones, and a sharper focus on its three core platforms: the Albany Graphite project, ZenGUARD and Triera. The company has moved to cut ...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Zentek Unveils Strategic Reset, Concentrates on Three Core Platforms
Positive
Jan 29, 2026
Zentek Ltd. has launched a strategic reset that narrows its focus to three core platforms—Albany Graphite, ZenGUARD and Triera—each governed by defined milestones, capital allocation criteria and a 24‑month roadmap, while pausing...
Business Operations and Strategy
Zentek’s Albany Graphite Wins Nuclear‑Grade Validation, Targeting High‑Value Specialty Markets
Positive
Jan 5, 2026
Zentek’s Albany Graphite subsidiary has received final independent test results confirming that its ultra‑high‑purity Albany graphite, when used in near‑net‑shaped graphite bricks, meets key performance benchmarks for...
Business Operations and StrategyProduct-Related Announcements
Zentek’s Albany Graphite Achieves Nuclear-Grade Performance, Targeting High-Value Specialty Markets
Positive
Jan 5, 2026
Zentek announced that independent testing has confirmed its Albany graphite achieves nuclear-grade performance in finished graphite bricks, meeting stringent benchmarks for strength, density, electrical performance and ultra-low impurity levels. W...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.